Tau(/proteins/tau Hyperphosphorylation And Neurofibrillary Tangles is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes 1.
Tau hyperphosphorylation and the subsequent formation of neurofibrillary tangles (NFTs) represent one of the two hallmark pathological features of Alzheimer's disease (AD) and are the defining pathology of the broader class of tauopathies. The tau] protein, encoded by the MAPT ([Microtubule-Associated Protein Tau] gene on chromosome 17q21.31, plays a crucial role in stabilizing microtubules in neurons. In AD, tau becomes abnormally hyperphosphorylated at more than 40 disease-specific sites, leading to its detachment from microtubules, mislocalization to the somatodendritic compartment, and self-aggregation into paired helical filaments (PHFs) that form NFTs (Ballatore et al., 2007). NFT burden correlates more strongly with neuronal loss and cognitive decline than does amyloid plaque density, making tau a critical therapeutic target 2.
Tau is predominantly expressed in neurons, where it binds to and stabilizes microtubules in axons, promoting microtubule assembly and regulating axonal transport dynamics (Ballatore et al., 2007). Tau is an intrinsically disordered protein that adopts multiple conformations depending on its phosphorylation state and binding partners. In its normal, moderately phosphorylated state, tau dynamically associates with microtubules, enabling the rapid remodeling required for axonal growth, synaptic plasticity, and intracellular cargo transport 3.
The human MAPT gene produces six isoforms through alternative splicing of exons 2, 3, and 10 (Goedert et al., 1989). These isoforms differ in:
In the adult human brain, 3R and 4R isoforms are expressed in roughly equal proportions. Disruption of this ratio — as occurs with MAPT mutations in frontotemporal dementia — drives tau pathology]. The longest isoform (2N4R) contains 441 amino acids 4.
Beyond phosphorylation, tau undergoes diverse post-translational modifications that regulate its biology and pathological potential (Martin et al., 2016):
Tau hyperphosphorylation results from a pathological imbalance: increased activity of tau kinases combined with decreased activity of tau phosphatases. Normal adult brain tau contains 2–3 moles of phosphate per mole of protein; in AD, this increases to 7–8 moles, with phosphorylation at over 40 of the 85 potential sites (Iqbal et al., 2005) 5.
[Glycogen Synthase Kinase]-3β ([GSK-3β): The most extensively studied tau kinase, GSK-3β phosphorylates tau at over 30 sites including critical residues Ser199, Ser202, Thr205, Thr231, Ser396, and Ser404 (Jope & Johnson, 2004). GSK-3β activity is increased in AD brain through several mechanisms: reduced inhibitory phosphorylation at Ser9 (due to impaired Akt/PI3K signaling), Aβ-mediated activation, and reduced sequestration by presenilin-1. GSK-3β polymorphisms are associated with AD risk, and overexpression of GSK-3β in transgenic mice produces tau hyperphosphorylation, synaptic loss, and cognitive deficits.
Cyclin-Dependent Kinase 5 ([CDK5): CDK5 requires p35 or p39 for activation and is essential for neuronal development (Baek et al., 2002). In AD, calcium-activated calpain cleaves p35 to p25, which constitutively activates CDK5 and mislocalizes it from the membrane to the cytosol. CDK5/p25 hyperphosphorylates tau at Ser202, Thr205, Ser235, and Ser404. Importantly, CDK5 primes tau for subsequent phosphorylation by GSK-3β, creating synergistic hyperphosphorylation.
c-Jun N-terminal Kinases (JNKs): JNK1, JNK2, and JNK3 are stress-activated MAP kinases that phosphorylate tau at multiple sites, particularly Ser202, Thr205, Ser396, and Ser422 (Ploia et al., 2011). JNK3, enriched in brain, is activated by Aβ oligomers and oxidative stress, and is elevated in AD brain. JNK-mediated tau phosphorylation is associated with both early-stage and advanced NFT pathology.
DYRK1A (Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A): Located in the Down syndrome critical region of chromosome 21, DYRK1A phosphorylates tau at Thr212 — an early pathological modification — and primes tau for GSK-3β (Wegiel et al., 2011). DYRK1A overexpression in trisomy 21 (Down syndrome) contributes to the near-universal development of AD pathology in these individuals by age 40.
Tyrosine Kinase 2 (TYK2): A recently identified tau kinase, TYK2 phosphorylates tau at tyrosine 29 (Y29), a modification that promotes tau aggregation (Nature Neuroscience, 2024). Partial inhibition of TYK2 reduces tau levels and aggregation in cell and mouse models, highlighting TYK2 as a promising novel therapeutic target.
Casein Kinase 1 (CK1): CK1δ and CK1ε phosphorylate tau at multiple C-terminal sites and are elevated in AD brain (Avila et al., 2003). CK1 activity correlates with Braak stage.
MARK (Microtubule Affinity-Regulating Kinases): MARK1-4 phosphorylate tau at KXGS motifs within the microtubule-binding repeats (Ser262, Ser356), directly detaching tau from microtubules and destabilizing the cytoskeleton.
Protein phosphatase 2A (PP2A accounts for approximately 70% of tau phosphatase activity in the brain (Liu et al., 2005). PP2A activity is significantly reduced (20–30%) in AD brain through:
PP1 and PP5 also contribute to tau dephosphorylation and show reduced activity in AD 6.
The tau aggregation pathway follows a nucleation-elongation mechanism:
NFT pathology follows a predictable anatomical progression described by the Braak staging system (Braak & Braak, 1991):
This stereotypical progression along connected neural circuits supports the prion-like spreading model of tau propagation] 8.
NFT density correlates more strongly with cognitive impairment than amyloid plaque burden across multiple studies (Nelson et al., 2012). Key evidence:
Tau spreads through synaptically connected neural networks via cell-to-cell transmission (de Calignon et al., 2012). Mechanisms include:
Tau "strains" — distinct conformational variants — may explain the different clinical presentations and neuropathological patterns of various tauopathies 9.
Phosphorylated tau species in cerebrospinal fluid (CSF) and blood are among the most informative AD biomarkers (Zetterberg et al., 2019):
Tau PET tracers — flortaucipir ([18F]AV-1451), [18F]MK-6240, [18F]PI-2620, and [18F]GTP1 — enable in vivo visualization of NFT distribution (Johnson et al., 2016). Second-generation tracers show improved specificity for AD tau over off-target binding. Tau PET signal correlates with cognitive impairment, predicts future decline, and is increasingly used in clinical trial endpoints 10.
Targeting tau kinases has been a major therapeutic strategy, though clinical translation has been challenging:
Sodium selenate, a PP2A activator, is in phase IIb clinical trials for progressive supranuclear palsy and frontotemporal dementia, with results expected in 2025. Preclinical data show reduced tau phosphorylation and improved cognition 11.
Methylene blue derivatives (LMTM/TRx0237) have been tested in phase III trials but showed limited efficacy as monotherapy. The aggregation inhibitor approach remains under investigation with newer chemical scaffolds 12.
Passive and active tau immunotherapies represent the most active clinical pipeline (Congdon et al., 2024):
Passive immunotherapy (monoclonal antibodies):
Active immunization (vaccines):
MAPT-targeting antisense oligonucleotides (ASOs) reduce total tau production. BIIB080 (IS 814907), an intrathecally delivered ASO, showed dose-dependent CSF tau reduction in phase I and is in phase II trials 13.
Tau hyperphosphorylation and aggregation are not specific to AD but define a broader class of tauopathies (Spillantini & Goedert, 2013):
| Tauopathy | Tau Isoforms | Key Features |
|---|---|---|
| Alzheimer's disease | 3R + 4R | NFTs with amyloid co-pathology |
| progressive supranuclear palsy | 4R | Globose tangles in subcortical nuclei |
| corticobasal degeneration | 4R | Astrocytic plaques, ballooned neurons |
| Pick's disease | 3R | Pick bodies in frontal/temporal cortex |
| Chronic traumatic encephalopathy | 3R + 4R | Perivascular NFTs at sulcal depths |
| [FTDP-17] | 3R or 4R | MAPT mutations, familial FTD |
| Primary age-related tauopathy | 3R + 4R | Medial temporal NFTs without significant Aβ |
Understanding shared mechanisms across tauopathies informs therapeutic development, as treatments effective in one tauopathy may benefit others 14.
The study of Tau Hyperphosphorylation And Neurofibrillary Tangles has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development 15.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions 16.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 19 references |
| Replication | 67% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 56%